Ratings American Healthcare REIT, Inc.

Equities

AHR

US3981823038

Real-time Estimate Cboe BZX Other stock markets 08:25:37 20/05/2024 pm IST			5-day change	1st Jan Change
14.54 ^USD	+0.28%		+3.34%	0.00%

14/05	Transcript : American Healthcare REIT, Inc., Q1 2024 Earnings Call, May 14, 2024
13/05	American Healthcare REIT Q1 Normalized FFO Declines, Revenue Rises; 2024 Normalized FFO Guidance Reaffirmed	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

This company will be of major interest to investors in search of a high dividend stock.
Analysts covering this company mostly recommend stock overweighting or purchase.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

Low profitability weakens the company.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Specialized REITs

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AMERICAN HEALTHCARE REIT, INC.	0.00%	1.67B	-	-
WELLTOWER INC.	+12.89%	60.56B		A-
HEALTHPEAK PROPERTIES, INC.	+0.73%	14B		A
OMEGA HEALTHCARE INVESTORS, INC.	-0.13%	7.57B		B
HEALTHCARE REALTY TRUST INCORPORATED	-7.89%	6.01B		B-
CARETRUST REIT, INC.	+12.47%	3.56B		C-
SABRA HEALTH CARE REIT, INC.	+0.45%	3.32B		C+
AEDIFICA SA	-5.50%	3.15B		B+
MEDICAL PROPERTIES TRUST, INC.	+4.79%	3.01B		C
NATIONAL HEALTH INVESTORS, INC.	+18.69%	2.89B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes